Bioreactors for Reparative Medicine - SBIR Direct Phase II (R44)

The summary for the Bioreactors for Reparative Medicine - SBIR Direct Phase II (R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Bioreactors for Reparative Medicine - SBIR Direct Phase II (R44): Major obstacles to the generation of functional tissues and their widespread use are limited by rudimentary tissue growth technologies. The purpose of this funding opportunity is to encourage small businesses to develop sophisticated and complex biomimetic culture systems that are capable of precise control of the cellular and 3-dimensional organ microenvironment, and which address the unique physiological dynamics of heart, lung and blood tissues. Projects awarded under this announcement should show evidence of developing or using good laboratory practice (GLP) standards and/or good manufacturing practices (GMP) standards, which play an important role in the adoption of many technologies used for pre-clinical research. Additionally, sources of cell variability should be discussed in the context of potential elements of measurement assurance and use of reference materials. For projects proposing clinical grade bioreactors and clinical investigations, an applicant must provide evidence that they have contacted the Food and Drug Administration (FDA) for guidance concerning the development of their bioreactor device, such as correspondence regarding investigational new drug (IND) application and status of their project in a timeline related to Federal regulatory approval processes.

Federal Grant Title:	Bioreactors for Reparative Medicine - SBIR Direct Phase II (R44)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-15-017
Type of Funding:	Grant
CFDA Numbers:	93.286, 93.837, 93.838, 93.839
CFDA Descriptions:	Discovery and Applied Research for Technological Innovations to Improve Human Health; Cardiovascular Diseases Research; Lung Diseases Research; Blood Diseases and Resources Research
Current Application Deadline:	Oct 14, 2016
Original Application Deadline:	Oct 14, 2016
Posted Date:	Jul 24, 2014
Creation Date:	Jul 24, 2014
Archive Date:	Nov 14, 2016
Total Program Funding:	$15,975,000
Maximum Federal Grant Award:	$750,000
Minimum Federal Grant Award:	none
Expected Number of Awards:	19
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following:
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria:

1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor;

2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture;

3. (i) SBIR and STTR. Be a concern which is more than 50 percent directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50 percent directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR

(ii) SBIR-only. Be a concern which is more than 50 percent owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50 percent of the concern; OR

(iii) SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with § 121.705(b) concerning registration and proposal requirements.

4. Has, including its affiliates, not more than 500 employees.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-017.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • New Approaches for Measuring Brain Changes Across Longer Timespans (R01 Clinical Trial Opt...; • Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historic...; • Understanding and Mitigating Health Disparities experienced by People with Disabilities ca...; • National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Op...; • Research on Bioethical Issues Related to Bionic and Robotic Device Development and Transla...; • Exploratory Grants (P20) for NIBIB Quantum Projects; • Nibib Research Supplements to Promote Clinical Resident Research Experiences; • Innovation in Molecular Imaging Probes
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...